This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Goldman Sachs Readies Bayou Battle: Street Whispers

In late March, with M&A interest already apparent, Goldman was nonetheless hired and Barclays was brought in as a co-advisor, splitting any prospective deal-related fees.

"Representatives of Barclays, Skadden and management of the company discussed that given the current state of the board's deliberations on potential strategic alternatives, uncertainty caused by the United States Supreme Court decision regarding the Affordable Care Act expected in June 2012, and that any transaction would be subject to the receipt of numerous regulatory approvals, although there was no certainty, it would be unlikely that a transaction involving the sale of the company would close prior to October 22, 2012," says Amerigroup in its proxy.

However, when inquiring about Amerigroup's July 9 sale - expected to close in early 2013 - and the terms of Goldman's warrants, the bank appears poised for the $233 million windfall if the deal were to stand as is.

When Amerigroup presented its advsors with a June 1 proposal to enter exclusive negotiations with WellPoint on a sale, LMPERS argues it's no surprise Goldman advised on moving forward.

Nevertheless, Amerigroup's proxy detailing its sale at length does also show a M&A process that took WellPoint's bid from the mid-$80s to $92, in a takeover that came at a 43% premium. That premium is also larger than Coventry Health Care's $5.7 billion takeover.

Still in a shareholder landscape dominated by activists and large pension funds, LMPERS' dogged and oftentimes-successful litigation may be a new check on C-Suite malfeasance.

Were Goldman's advice in Amerigroup's sale to WellPoint to yield similar discovery and judicial findings as those stemming from LMPERS' El Paso suit, it might be cause for investment bankers and executives to think twice before assembling sweetheart deals for everyone but shareholders.

-- Written by Antoine Gara in New York
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WLP $136.01 1.43%
AET $114.63 0.00%
GS $164.50 0.13%
AAPL $95.03 0.21%
FB $116.73 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs